Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19.

Detalles Bibliográficos
Autores principales: Banerjee, Rahul, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604917/
https://www.ncbi.nlm.nih.gov/pubmed/33139895
http://dx.doi.org/10.1038/s41571-020-00448-y
_version_ 1783604215301537792
author Banerjee, Rahul
Prasad, Vinay
author_facet Banerjee, Rahul
Prasad, Vinay
author_sort Banerjee, Rahul
collection PubMed
description Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19.
format Online
Article
Text
id pubmed-7604917
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76049172020-11-02 Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19 Banerjee, Rahul Prasad, Vinay Nat Rev Clin Oncol News & Views Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19. Nature Publishing Group UK 2020-11-02 2021 /pmc/articles/PMC7604917/ /pubmed/33139895 http://dx.doi.org/10.1038/s41571-020-00448-y Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News & Views
Banerjee, Rahul
Prasad, Vinay
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
title Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
title_full Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
title_fullStr Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
title_full_unstemmed Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
title_short Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19
title_sort pragmatic trials with prespecified subgroups: what oncologists can learn from covid-19
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604917/
https://www.ncbi.nlm.nih.gov/pubmed/33139895
http://dx.doi.org/10.1038/s41571-020-00448-y
work_keys_str_mv AT banerjeerahul pragmatictrialswithprespecifiedsubgroupswhatoncologistscanlearnfromcovid19
AT prasadvinay pragmatictrialswithprespecifiedsubgroupswhatoncologistscanlearnfromcovid19

Ejemplares similares